Pharmacokinetics and pharmacodynamics of FK143, a nonsteroidal inhibitor of steroid 5α-reductase, in healthy volunteers

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 354-366

  Katashima, Masataka ^a   Irino, Tadayoshi ^b   Shimojo, Fumio ^b   Kawamura, Akio ^b   Kageyama, Hiromitu ^b   Higashi, Naoko ^b   Miyao, Yasuhiro ^b   Tokuma, Yoji ^b   Hata, Takehisa ^b   Yamamoto, Koujirou ^b   Sawada, Yasufumi ^b   Iga, Tatsuji ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ARTICLE; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; VOLUNTEER;

ADMINISTRATION, ORAL; AREA UNDER CURVE; BLOOD PROTEINS; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FOLLICLE STIMULATING HORMONE; HUMANS; HYDROCORTISONE; INDOLES; LUTEINIZING HORMONE; MALE; MIDDLE AGED; PHENYLBUTYRATES; PROTEIN BINDING; TESTOSTERONE 5-ALPHA-REDUCTASE; TIME FACTORS;

EID: 13144257784     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90167-9     Document Type: Article

References (40)

1. Anderson KM, Liao S. Selective retention of dihydrotestosterone by prostatic nuclei. Nature 1968;219; 277-9.
2. Bruchovsky N, Wilson JD. The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968;243:2012-21.
3. Bruchovsky N, Wilson JD. The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 1968;243:5953-60.
4. Hammond GL. Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J Endocrinol 1978;78:7-19.
5. Sandberg AA. Endocrine control and physiology of the prostate. Prostate 1980;1:169-84.
6. Gloyna RE, Siiteri PK, Wilson DJ. Dihydrotestosterone in prostatic hypertrophy; I: the formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 1970;49:1737-45.
7. Gloyna RE, Siiteri PK, Wilson DJ. Dihydrotestosterone in prostatic hypertrophy; II: the formation and content of dihydrotestosterone on prostatic growth in the dog. J Clin Invest 1970;49:1746-53.
8. Hudson RW, Moffitt PM, Owens WA. Studies of the nuclear 5α-reductase of human prostatic tissue: comparison of enzyme activities in hyperplastic, malignant and normal tissue. Can J Biochem Cell Biol 1982;61: 750-5.
9. Imperato-McGinley J, Peterson RE, Gantier T, Sturla E. Male pseudo-hermaphrodism secondary to 5α-reductase deficiency: a model for the role of androgens in both the development of the male phenotype and the evolution of a male gender identity. J Steroid Biochem 1979;11:637-45.
10. Isaacs JT, Coffey DS. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 1981;108:445-53.
11. Moore RJ, Gazak JM, Quebbeman JF, Wilson JD. Concentration of dihydrotestosterone and 3α-androstan-diol in naturally occurring and androgen-induced prostatic hyperplasia in the dog. J Clin Invest 1979;64:1003-10.
12. Brooks JR, Baptista EM, Berman C, Ham EA, Hichens M, Johnston DBR, et al. Response of rat ventral prostate to a new and novel 5α-reductase inhibitor. Endocrinology 1081;109:830-6.
13. Wenderoth UK, George FW, Wilson JD. The effect of a 5α-reductase inhibitor on androgen-mediated growth of the dog prostate. Endocrinology 1983;113:569-73.
14. Shao TC, Kong AK, Marafelia P, Cunningham GR. Effects of finasteride on the rat ventral prostate. J Androl 1993;14:79-86.
15. Lamb JC, English H, Levandoski PL, Rhodes GR, Johnson RK, Isaacs JT. Prostatic involution in rats induced by a novel 5α-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology 1992;130:685-94.
16. Peters DH, Sorkin EM. Finasteride - a review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993;46:177-208.
17. The Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992;327:1185-91.
18. Rittmaster RS. Drug therapy - finasteride. N Engl J Med 1994;330:120-5.
19. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996;30: 16-27.
20. Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet 1991;16:15-21.
21. Vermeulen A, Giagulli VA, DeSchepper P, Buntinx A, Stoner E. Hormonal effects of an orally active 4-azasteroid inhibitor of 5α-reductase in humans. Prostate 1989;14:45-53.
22. Hirosumi J, Nakayama O, Fagan T, Sawada K, Chida N, Inami M, et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase; (1): in vitro effects on human and animal prostatic enzymes. J Steroid Biochem Mol Biol 1995;52:357-63.
23. Hirosumi J, Nakayama O, Chida N, Inami M, Fagan T, Sawada K, et al. FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase; (2): in vivo effects on rat and dog prostate. J Steroid Biochem Mol Biol 1995;52:365-73.
24. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Pharmacokinetic and pharmacodynamic study of a new non-steroidal 5α-reductase inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino] benzoyl]-1H-indol-1-yl]-butyric acid, in rats. J Pharmacol Exp Ther [in press].
25. Katashima M, Yamamoto K, Haraguchi K, Tokuma Y, Hata T, Sawada Y, et al. Tissue distribution kinetics of a new nonsteroidal testosterone 5α-reductase inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino] benzoyl]-1H-indol-1-yl]-butyric acid, in rats. Drug Metab Dispos 1997;25:1051-8.
26. Ko HC, Jusko WJ. Pharmacodynamic modeling of finasteride, a 5α-reductase inhibitor. Pharmacotherapy 1995;15:509-11.
27. Roberts J, Turner N. Age and diet effects on drug action. Pharmacol Ther 1988;37:111-49.
28. Melander A, McLean A. Influence of food intake on presystemic clearance of drugs. Clin Pharmacokinet 1983;8:286-96.
29. Nomeir AA, Mojaverian P, Kosoglou T, Affrime MB, Nezamis J, Radwanski E, et al. Influence of food on the oral bioavailability of loratadine and pseudoephedrine from extended-release tablets in healthy volunteers. J Clin Pharmacol 1996;36:923-30.
30. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993;10:1093-5.
31. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
32. Kabasakalian P, Katz M, Rosenkrantz B, Townley E. Parameters affecting absorption of griseofulvin in a human subject using urinary metabolite excretion data. J Pharm Sci 1970;59:595-600.
33. Klompmarker IJ, Wierda JMKH, Sluiter WJ, Uges DRA, Haagsma EB, Verwer R, et al. Pharmacokinetics of cyclosporine A after intravenous and oral administration in liver transplant patients measured with high-performance liquid chromatography. Ther Drug Monit 1993;15:60-4.
34. Blouin RA, Stoeckel K. Cefetamet pivoxil clinical pharmacokinetics. Clin Pharmacokinet 1993;25:172-88.
35. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993;92:903-10.
36. Wright F, Mowszowicz I, Mauvais-Jarvis P. Urinary 5α-androstane-3α,17β-diol radioimmunoassay, a new clinical evaluation. J Clin Endocrinol Metab 1978;47: 850-4.
37. Ishimura T, Edmiston WA, Pages L, Horton R. Splanchnic extraction and conversion of testosterone and dihydrotestosterone in man. J Clin Endocrinol Metab 1978;46:528-33.
38. Kojo H, Nakayama O, Hirosumi J, Chida N, Notsu Y, Okuhara M. Novel steroid 5α-reductase inhibitor FK143: its dual inhibition against the two isozymes and its effect on transcription of the isozyme genes. Mol Pharmacol 1995;480:401-6.
39. Kinouchi T, Horton R. 3α-Androstanediol kinetics in man. J Clin Invest 1974;54:646-53.
40. Tremblay RR, Kowarski A, Park IJ, Migeon CJ. Blood production rate of dihydrotestosterone in the syndrome of male pseudohermaphroditism with testicular feminization. J Clin Endocrinol Met 1972;35: 101-7.